{"entity":{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","aka":["GeneQuantum Healthcare (Suzhou) Co., Ltd."],"tldr":"GeneQuantum Healthcare (Suzhou) is a China-based biotechnology company running 2 late-stage cancer trials of GQ1005 and phase II in HER2-positive breast cancer.","summary":"GeneQuantum Healthcare (Suzhou), based in Suzhou, China, is a biotechnology company. GeneQuantum Healthcare develops bioconjugate therapeutics, including antibody-drug conjugates, using proprietary site-specific conjugation technologies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing GQ1005 and phase II in HER2-positive breast cancer. The largest, NCT06464055 (A Study of GQ1010 in Subjects With Advanced Solid Tumours), plans to enrol 260 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.genequantum.com"},{"label":"ClinicalTrials.gov: trials led by GeneQuantum Healthcare (Suzhou)","url":"https://clinicaltrials.gov/search?lead=GeneQuantum%20Healthcare%20(Suzhou)%20Co.%2C%20Ltd."},{"label":"Pipeline page","url":"https://www.genequantum.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["gq1005"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06464055"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.genequantum.com","founded":2013,"stage":"growth","investors":[],"funding":[]},"route":"/companies/genequantum-healthcare-suzhou/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/"}],"trial":[{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/"},{"id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/"}]}}